Phase 4 Completed N=26 Treatment

CEV With/Without Periocular Carboplatin Chemotherapy for Extraocular Retinoblastoma

Retinoblastoma

Source: ClinicalTrials.gov NCT02319486 ↗

Enrolled (actual)

Serious AEs

57.7%

Results posted

Mar 2015

Primary outcomePrimary: Event Free Survival Rate — 7; 4 participants — p=0.034

Summary

This study will evaluate a uniform chemotherapy protocol for nonmetastatic extraocular retinoblastoma

Outcome Measures

Outcome	Result	p-value
PRIMARY Event Free Survival Rate	7; 4	0.034 sig

Eligibility Criteria

Inclusion Criteria

IRSS stage II or stage IIIa RB patients.
for patients with IRSS stage II disease, if scleral surface invasion alone was observed, only systemic chemotherapy was administered, whereas other IRSS stage II and IIIa patients received systemic chemotherapy plus additional local chemotherapy.
no tumor-related treatment was given prior to this chemotherapy regimen.

Exclusion Criteria

metastasis, including lymph node metastasis.
the diagnosis of IRSS stage I or above in the non-target eye.

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT02319486). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.